Research Desk Line-up: Ascendis Pharma Post Earnings Coverage
LONDON, UK / ACCESSWIRE / June 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Tel Aviv, Israel based Cellect Biotechnology Ltd. (NASDAQ: APOP). The stem-cell Company announced on June 12, 2017, that it has received an official notice of allowance for a patent (Application No. 14/383,288) from the US Patent and Trademark Office. The application covers a key composition of matter as well as the method of use. The Patent with regards to Cellect Biotech's Flagship Technology - the ApoGraft™ - and the use of this technology in device. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Ascendis Pharma A/S (NASDAQ: ASND) for due-diligence and potential coverage as the Company announced on May 23, 2017, its financial results for Q1 2017 which ended on March 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Ascendis Pharma when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on APOP; also brushing on ASND. Go directly to your stock of interest and access today's free coverage at:
Sharing his views on the USPTO's communication, Dr. Shai Yarkoni, CEO of Cellect Biotech said:
"This patent is a fundamental base for the future commercialization of our global business. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, we believe that Cellect has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments."
USPTO's notice of allowance and its implications for Cellect Biotech
The current patent in addition to the patents granted earlier for ApoGraft™ gives Cellect Biotech complete protection; firstly, protection against any device that uses apoptosis for cell selection; and secondly, protection against the method for using such device. The device is designed in such a manner that it enables single step cell selection in a simplified setting that it can be used in any off-the-shelf product. At present, such technology does not exist and can cover a wide range of unmet medical needs.
The devices that can easily use this patented technology could be containers like a bag, column, tube, bottle, vial, flask, or bioreactor which are made out of biocompatible material. The inner surface of such containers could be lined by a biologically active apoptosis-inducing ligand. The device could be adapted for cell selection by apoptosis-sensitive cells.
As the devices using the technology currently do not exist and in the future if such devices are developed and approved for use, they would help in the selection of stem-cells and are expected to reduce fatal inflammatory responses such as graft versus host disease (GvHD) associated with stem-cell transplantations. Devices using Cellect Biotech's ApoGraft™ technology have other multiple application and use like bone marrow transplants and other immune related medical conditions such as Diabetes type-I, inflammatory bowel disease, etc.
About Cellect Biotech and its Flagship Technology ApoGraft™
Cellect Biotech was founded by Kasbian Nuriel Chirich, Dr. Shai Yarkoni, and Dr. Nadir Ashkenazy in 2011 to work on making regenerative medicine into reality. They realized that for regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect Biotech wanted to be at the forefront and the main provider of stem-cell technologies that were trivial, safe, and use in inexpensive process.
After a 15 year in-depth research Cellect Biotech came out with its Flagship Technology - the ApoGraft™. This novel technology is designed to isolate stem-cells from any given tissue. Cellect Biotech's ApoGraft™ is backed by 7 families of patents and is on its way to become the industry-wide standard for enabling the use of stem-cells in a myriad of regenerative medicine treatments. This technology will enable pharma Companies, medical research centers, and hospitals to rapidly isolate stem-cells in quantity and quality that will allow stem-cell related treatments and procedures.
Cellect Biotech's ApoGraft™ is a breakthrough technology isolating stem-cells through Apoptosis. Apoptosis is a process of programmed death of cells which occurs as a normal and controlled part of an organism's growth or development. Cellect Biotech's key finding is that in an apoptotic environment, mature cells die while stem-cells survive and even flourish. ApoGraft™ technology allows the functional selection of stem-cells through an apoptotic process. One of the examples as to how Cellect Biotech is promoting the use of this technology, is by lacing various containers (such as infusion bags, test tubes etc.) with an apoptosis inducing protein and within hours from infusing cells into the container, a safe, effective, and non-toxic mass of mostly enriched stem-cells remain.
Last Close Stock Review
At the close of trading session on Tuesday, June 13, 2017, Cellect Biotechnology's stock price rose 6.59% to end the day at $8.73. A total volume of 33.15 thousand shares were exchanged during the session. In the last three months and previous six months, shares of the Company have soared 39.46% and 165.50%, respectively. Moreover, the stock skyrocketed 182.52% since the start of the year. The stock currently has a market cap of $939.20 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily